With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease – FiercePharma

1. With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease FiercePharma
2. Travere Therapeutics drug approved for rare kidney disease – STAT STAT
3. Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy Yahoo Finance
4. US FDA approves Travere Therapeutics kidney disorder drug TODAY
5. Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy Yahoo Finance
6. View Full Coverage on Google News

Read original article here